According to a new study, metformin, a drug used as the treatme of the first line for type 2 diabetes, was associated with a 5 % reduction in death. The study adds to a growing evidence that this common drug may have ai -aging properties.
According to Flow Genio News Agency, For decades, metformin has been the treatme for the first line for type 2 diabetics who cannot corol their blood sugar alone through diet and exercise. In rece years, research has shown that the health reinforced properties of this drug exceed diabetes and are associated with a decrease in the risk of demeia and reduced knee arthritis pain.
A new study led by the University of California, San San Diego, has shown that the use of metformin by women with type 2 diabetes is associated with an increase in life, which means that it is up to a very old age like 5 years and more.
Metformin is known as the Foxo3 gene activator, a gene that is heavily involved in aging and longevity processes. It is involved in regulating cellular response to stress, such as oxidative stress, which is a key factor in aging. It activates genes that increase cell survival and resistance to planned cell or apoptosis and are also involved in regulating DNA repair mechanisms.
However, studies on the relationship between metformin and the lifespan in mice and humans have so far produced differe results. While these previous studies have mainly focused on the relationship between metformin and death or disease, no observational or randomized clinical trial (RCT) has examined whether metformin increases exceptional life span. Therefore, the researchers in this new study explored this issue and used a research method called the “Transie Transie Simulation Framework” that is a method that simulates the design of a clinical trial, when it is not possible to do so.
They examined the data from the study of women’s health initiative, including four postmenopausal women who had recely developed type 2 diabetes and began treating ai -diabetic drugs. The study of a large group of women in the United States has pursued for more than 5 years, from middle -aged to age 5 and older. Researchers specifically compared women who only consumed metformin with women who only used other blood glucose reduced drugs called sulfonyl. They ensured that the two groups were as similar in terms of age, lifestyle, health and other factors to make a fair comparison.
The key finding of this study was that women who started metformin were at risk of dying before the age of 5. The finding shows that the onset of metformin after detecting type 2 diabetes is more likely to be more likely to live longer than the onset of sulfonil urea.
The researchers say: In this first targeted trial that simulated metformin and exceptional life, we found that the start of metformin extends exceptional life span among women with type 2 diabetes compared to the onset of sulfonyl urea.
The most importa limitations of this study were the mere examination of women, the failure to consider the non -diabetic comparison group, and the failure of the placebo consumer comparison group. In fact, it is because of these limitations that the researchers recommend that the findings should be ierpreted with caution. They also emphasize that future studies are needed to determine the main cause of the relationship between metformin and longevity.
The poi is that this study is in its early stages, which means that you should not decide to take diabetes or change diabetes without prescription.
Any medication should be taken with the opinion and consultation of the doctor, and arbitrary use of the drug can be accompanied by irreparable results.
The end of the message
(tagstotranslate) Diabetes (T) Extension of Longevity
